Our previous studies have demonstrated that sorafenib can promote the dissemination of hepatocellular carcinoma (HCC) through downregulation of HTATIP2, a suppressor of tumor growth and metastasis that is associated with inhibition of angiogenesis. Here, we investigated the predictive values of the HTATIP2 level and microvessel density (MVD) with or without sorafenib administration for HCC. Three independent cohorts were included. Using tissue microarray, we assessed the relationship between HTATIP2 expression/MVD and overall survival. The results showed that high HTATIP2 expression and a low MVD value were independent protective prognostic factors after curative HCC resection (297 cases/cohort 1); however, both parameters were converted to independent negative prognostic indicators for patients with postsurgical sorafenib treatment (69/143 cases/cohort 2; P<0.05 for all). This same relationship was observed in patients that received sorafenib treatment for advanced HCC (83 cases/cohort 3; efficacy measures and survival analyses, P<0.05 for all). Moreover, the combination of HTATIP2 and MVD had better power to predict patient death and disease recurrence (P<0.001 for both). We conclude that the combination of HTATIP2 and MVD predicts the converse survival of HCC with or without sorafenib intervention. Our findings can assist in the selection of candidates for personalized treatment with sorafenib.
[1]Fudan Univ, Dept Pancreat & Hepatobiliary Surg, Shanghai Canc Ctr, Shanghai 200433, Peoples R China.
[2]Fudan Univ, Dept Oncol, Shanghai Med Coll, Shanghai 200433, Peoples R China.
[3]Fudan Univ, Pancreat Canc Inst, Shanghai 200433, Peoples R China.
[4]Fudan Univ, Key Lab Carcinogenesis & Canc Invas, Liver Canc Inst, Zhongshan Hosp,Chinese Minist Educ, Shanghai 200433, Peoples R China.
[5]Tianjin Med Univ, Canc Inst & Hosp, Key Lab Canc Prevent & Therapy, Dept Hepatobiliary Surg, Tianjin, Peoples R China.
(8.0+极速模式)